Pharma MES in Clinical Manufacturing: What Leaders Should Be Prioritizing in 2026
At Pharma MES USA 2026 in Boston, one theme came through clearly:
The challenge has shifted beyond selecting the right manufacturing execution system (MES).
The focus is now on operating it effectively.
As organizations expand into clinical manufacturing environments such as cell and gene therapy, early-stage production, and CDMOs, the complexity evolves. Systems are largely in place. Success is determined by how those systems perform under constant change.
For many teams, attention has moved from deploying pharmaceutical MES software to sustaining performance, compliance, and flexibility in operational realities.
Key themes shaping pharma MES in clinical manufacturing
1. Clinical manufacturing changes everything
Clinical environments operate at a fundamentally different pace.
In commercial pharma manufacturing, change is controlled and infrequent. In clinical settings, change is continuous. Some teams manage multiple change controls per day, driven by ongoing process development, evolving data, and patient-specific variability.
In cell and gene therapy, each batch may represent an individual patient. Variability is inherent, and speed is directly tied to patient outcomes.
These conditions place new demands on pharma MES software and electronic batch record (EBR) systems, which must support real-time adaptability while maintaining full traceability and compliance.
2. Traditional MES assumptions break in clinical
Most manufacturing execution systems were designed around standardization.
Clinical manufacturing requires flexibility. Rigid workflows, predefined recipes, and assumptions of stability create friction as processes evolve in real time.
Efforts to define every variation upfront often result in overly complex batch record software that becomes difficult to maintain and validate.
Modern life sciences software must balance flexibility with control, enabling teams to adapt without compromising compliance.
3. MES is easier to implement than it is to operate
Across organizations, implementing a pharma MES is no longer the primary barrier. Complexity emerges after go-live, as teams sustain operations within validated environments.
The focus shifts to governance, validation, change management, and coordination across Quality, IT, and Manufacturing.
Teams are navigating the structure required to operate systems effectively at scale.
Success is increasingly determined by the operating model surrounding the MES software.
4. Validation is evolving and becoming strategic
Validation is shifting from traditional Computer System Validation (CSV) toward Computer Software Assurance (CSA).
Risk-based approaches are replacing one-size-fits-all validation, allowing teams to focus on high-impact areas. This reduces unnecessary testing and accelerates system updates while maintaining compliance.
For electronic batch record systems and pharma MES platforms, this enables faster iteration and more efficient change management.
Validation now plays a direct role in enabling speed and operational efficiency.
5. Tech transfer is a knowledge problem
Tech transfer requires more than moving recipes or batch records between environments.
It depends on preserving the reasoning behind decisions, the context of changes, and the learning generated during development.
Today, that knowledge is often fragmented across systems and teams. This leads to repeated work, slower scale-up, and lost insights during transitions from clinical to commercial manufacturing.
Modern pharmaceutical MES platforms must support structured knowledge capture alongside capabilities like review by exception and traceable data management.
What this means for pharma manufacturers
The implications are immediate.
Pharma MES functions as an operational capability that requires ongoing ownership. Long-term performance depends on governance and the ability to sustain continuous change.
Systems must support flexibility within validated frameworks, particularly within electronic batch record systems.
A phased approach supports stronger adoption, allowing teams to scale intentionally while refining processes over time.
Clear problem definition remains essential. Organizations that align strategy before selecting tools build more cohesive and effective life sciences software environments.
Designing the next generation of pharma MES
The next generation of pharma MES software is taking form in alignment with these emerging realities.
Recipe authoring must become simpler and faster, reducing the burden of creating and maintaining complex workflows. Execution must become more flexible, allowing teams to adapt processes in real time while maintaining full traceability.
Equally important is the ability to support review by exception, reducing manual review effort and accelerating batch release while maintaining compliance.
Systems must also evolve beyond execution. They need to capture not only what was done, but why it was done, enabling more effective tech transfer and continuous improvement.
Reducing reliance on custom code will be critical. Highly customized batch record software introduces validation overhead and slows down change. Future systems will need to operate within validated, configurable frameworks.
This is where a Pharma First MES approach becomes increasingly important, aligning system design with the realities of regulated manufacturing environments.
The direction is clear.
MES must support speed, flexibility, and continuous evolution.
Where AI fits in this evolution
AI was not the central focus of the discussion, but it sits just beneath the surface of many of these challenges.
The consistent signal across organizations is that foundational work is still underway. Data quality, governance, and system maturity remain the priority.
Until those foundations are in place, AI will remain limited in its ability to scale within pharma manufacturing environments.
This reinforces a broader point:
Advanced capabilities depend on disciplined execution of core systems like pharma MES and electronic batch record platforms.
MES as a long-term discipline
One of the most important takeaways from the panel is that no organization has fully solved this.
Every team is still evolving.
Pharma MES requires the capability to operate systems effectively and scale with confidence.
If you are navigating this shift, it is worth stepping back to evaluate how your pharma MES software, validation approach, and operating model support long-term performance.
Because in clinical manufacturing, the system is only the foundation.
How it is operated is what defines success.
If you are evaluating how your MES strategy supports long-term performance, we welcome the opportunity to compare approaches and share what we are seeing across the industry.
👉 Connect with us at sales@poms.com.
For a deeper look at how AI is shaping pharma manufacturing alongside MES, read more here:
